Dupilumab in Asia-Pacific patients with persistent asthma

Conclusion: In patients with persistent type 2 asthma and no OCS maintenance, DPL led to rapid, sustained improvement in lung function and asthma control, reduced AER, and was generally well tolerated.

Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Zhang, Q., Nanshan, Z., Dhooria, S., Fu, X., Lin, J., Li, W., Laws, E., Mannent, L. P., Wang, Y., Li, V., Li, A., Hu, C.-C., Lederer, D. J., Abdulai, R. M., Robinson, L. B., Zhang, Q. Tags: Airway pharmacology and treatment Source Type: research